Joaquim Bellmunt
#114,226
Most Influential Person Now
Researcher
Joaquim Bellmunt's AcademicInfluence.com Rankings
Joaquim Bellmuntmedical Degrees
Medical
#1604
World Rank
#1961
Historical Rank
Urology
#7
World Rank
#8
Historical Rank
Oncology
#75
World Rank
#79
Historical Rank
Joaquim Bellmuntphilosophy Degrees
Philosophy
#4901
World Rank
#7574
Historical Rank
Logic
#2265
World Rank
#3223
Historical Rank
Download Badge
Medical Philosophy
Joaquim Bellmunt's Degrees
- Doctorate Medicine University of Barcelona
- PhD Medicine University of Barcelona
Why Is Joaquim Bellmunt Influential?
(Suggest an Edit or Addition)Joaquim Bellmunt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial (2016) (2837)
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017) (2591)
- Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma (2017) (2186)
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (2014) (2071)
- EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014) (1877)
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (2017) (1477)
- EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. (2011) (1449)
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017) (1289)
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2011) (1178)
- Guidelines on Prostate Cancer (2013) (927)
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. (2017) (880)
- EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2014) (861)
- Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010) (784)
- [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. (2011) (733)
- Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. (2009) (678)
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. (1998) (649)
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2018) (574)
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. (2012) (568)
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. (2020) (486)
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer (2012) (440)
- Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. (2011) (437)
- Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. (2012) (423)
- Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. (2010) (382)
- Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. (2014) (365)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
- Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. (2010) (335)
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (2017) (322)
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. (2010) (316)
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. (2017) (307)
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. (2006) (300)
- What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. (2017) (289)
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
- Congestive heart failure risk in patients with breast cancer treated with bevacizumab. (2011) (268)
- PD-L1 expression in nonclear-cell renal cell carcinoma. (2014) (246)
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. (2015) (244)
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019) (244)
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. (2011) (233)
- A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. (2012) (223)
- Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. (2014) (222)
- Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma (1997) (221)
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. (2011) (220)
- The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. (2017) (215)
- A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. (2014) (211)
- Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. (2007) (203)
- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer (2015) (203)
- Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. (2014) (202)
- Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. (2014) (200)
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. (2013) (197)
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. (2020) (191)
- Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. (2016) (188)
- Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma (2018) (185)
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma (2021) (179)
- DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma (2017) (176)
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2016) (169)
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. (2008) (167)
- Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. (2000) (167)
- ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. (2013) (165)
- Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. (2017) (164)
- Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. (2015) (163)
- Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. (2010) (162)
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. (2013) (152)
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer (2015) (152)
- Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. (2009) (151)
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. (2012) (150)
- Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. (2014) (147)
- Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine (2002) (142)
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel (2015) (138)
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. (2021) (133)
- Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. (2007) (127)
- ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. (2011) (127)
- Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. (2003) (126)
- Toxicities of targeted therapy and their management in kidney cancer. (2011) (126)
- Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology (2017) (126)
- Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. (2015) (123)
- Management of metastatic bladder cancer. (2019) (120)
- Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. (2012) (119)
- The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. (2019) (116)
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. (2011) (116)
- Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. (2015) (114)
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. (2020) (112)
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. (2013) (112)
- A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. (2001) (112)
- The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review (2018) (109)
- EORTC-GU group expert opinion on metastatic renal cell cancer. (2009) (108)
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
- Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). (2014) (105)
- New therapeutic challenges in advanced bladder cancer. (2012) (101)
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. (2015) (100)
- Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study (2018) (99)
- Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. (2016) (95)
- Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. (2017) (94)
- Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. (2017) (94)
- Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. (2018) (93)
- Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. (2010) (89)
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. (2018) (89)
- The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. (2009) (89)
- Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). (2009) (89)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (84)
- ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer (2018) (83)
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (81)
- Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population‐based analysis (2015) (80)
- Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma (2014) (80)
- Endobronchial metastatic disease: Analysis of 32 cases (1996) (80)
- Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. (2016) (78)
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study (2015) (76)
- Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. (2010) (76)
- Strategies to design clinical studies to identify predictive biomarkers in cancer research. (2017) (74)
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. (2011) (73)
- Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. (2020) (73)
- Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. (2020) (73)
- The evolving understanding of microRNA in bladder cancer. (2014) (73)
- Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites (2018) (73)
- Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (70)
- Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. (2013) (69)
- New treatment options for metastatic renal cell carcinoma (2017) (67)
- Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives (2017) (67)
- A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). (2015) (66)
- Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). (2010) (65)
- Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. (2016) (65)
- Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. (2017) (65)
- Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials (2017) (63)
- Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study (2016) (62)
- IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). (2016) (61)
- Erdafitinib for the treatment of metastatic bladder cancer (2019) (60)
- Experience with sorafenib and adverse event management. (2011) (60)
- Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents (2007) (59)
- Upper tract urothelial carcinoma: a different disease entity in terms of management (2016) (59)
- Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). (2017) (59)
- Faculty Opinions recommendation of Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. (2009) (58)
- Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. (2009) (58)
- Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. (2018) (57)
- Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. (2013) (57)
- Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. (2013) (57)
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. (2016) (56)
- Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles (2016) (56)
- Comparative effectiveness of robot-assisted vs. open radical cystectomy. (2017) (56)
- LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER (2014) (56)
- Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. (2017) (55)
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. (2016) (55)
- Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries (2014) (54)
- Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. (1996) (53)
- Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy (2017) (53)
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. (2019) (53)
- Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. (2017) (52)
- Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches (2011) (52)
- Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy (1992) (52)
- Adrenocortical carcinoma: the management of metastatic disease. (2014) (52)
- Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. (2018) (51)
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (2011) (51)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
- Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). (2017) (50)
- Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. (2020) (50)
- Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. (2019) (49)
- New agents for prostate cancer. (2014) (49)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
- Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)† (2015) (48)
- Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma (2014) (48)
- Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. (2015) (48)
- Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients (2014) (47)
- Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. (2007) (47)
- The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. (2011) (47)
- Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma (2015) (46)
- Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM) (2010) (46)
- Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (2018) (46)
- Targeted therapies and the treatment of non-clear cell renal cell carcinoma. (2013) (45)
- Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma (2016) (45)
- A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. (2015) (45)
- [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. (2011) (45)
- The medical management of prostate cancer: a multidisciplinary team approach (2007) (45)
- Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. (2017) (44)
- Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First‐Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta‐Analysis (2017) (44)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) with or without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The Mainsail Trial (2012) (44)
- Current vaccination strategies for prostate cancer. (2012) (43)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (43)
- Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). (2018) (43)
- Urothelial carcinoma management in elderly or unfit patients☆ (2016) (43)
- IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC). (2020) (42)
- Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. (2004) (42)
- Randomized Phase IIIB Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from Intoract (2012) (40)
- Endobronchial metastatic disease: analysis of 32 cases. (1996) (40)
- Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer (2020) (40)
- Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. (2017) (40)
- Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial). (2014) (39)
- The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations (2009) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone (2012) (39)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (38)
- New perspectives in the therapy of castration resistant prostate cancer. (2012) (38)
- SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer (2019) (37)
- Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. (2012) (37)
- HER2 as a target in invasive urothelial carcinoma (2015) (37)
- Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. (2015) (36)
- Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. (2017) (36)
- Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial (2021) (36)
- PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). (2016) (36)
- Diagnosis and local treatment with curative intent (2018) (36)
- Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. (2010) (35)
- What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? (2013) (35)
- Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer (2002) (35)
- Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. (2017) (35)
- Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid (2011) (35)
- A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma (2014) (35)
- New drugs and new approaches in metastatic bladder cancer. (2003) (34)
- FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression (2020) (34)
- Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. (2018) (34)
- Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. (2020) (34)
- Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
- Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. (2014) (33)
- SEOM clinical guidelines for the treatment of renal cell carcinoma (2014) (33)
- Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. (2013) (32)
- Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study (2017) (32)
- Genitourinary tumors, non-prostate (2012) (31)
- p53 oncoprotein as a prognostic indicator in patients with breast cancer. (1998) (31)
- Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. (2005) (31)
- Treatment of metastatic cancer (2008) (31)
- Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer (2020) (31)
- Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
- Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes (2018) (31)
- The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients (2012) (30)
- Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review (2013) (30)
- Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB) (2013) (29)
- Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease (2017) (29)
- Perspectives on treatment of metastatic castration-resistant prostate cancer. (2013) (29)
- Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. (1996) (29)
- A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. (2013) (29)
- Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators (2017) (29)
- Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. (2013) (28)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. (2017) (28)
- Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET (2010) (28)
- Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. (2006) (27)
- Chemotherapy for metastatic or unresectable bladder cancer. (2007) (27)
- Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. (2014) (27)
- Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients (2010) (26)
- Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. (2004) (26)
- Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. (2016) (26)
- Optimal management of metastatic renal cell carcinoma: an algorithm for treatment (2009) (26)
- Future directions and targeted therapies in bladder cancer. (2015) (25)
- A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options (2011) (25)
- Differential Expression of PD‐L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications (2017) (25)
- Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA (2013) (25)
- Chemotherapy for older patients with prostate cancer (2007) (25)
- Estrogen Receptor Beta Displays Cell Cycle-Dependent Expression and Regulates the G1 Phase through a Non-Genomic Mechanism in Prostate Carcinoma Cells (2008) (25)
- Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (2012) (25)
- Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial (2019) (25)
- A phase 3 study of first-line durvalumab (MEDI4736) {+/-} tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE. (2016) (25)
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma (2018) (25)
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) (2018) (24)
- European Early Phase II Dose‐Finding Study of Droloxifene in Advanced Breast Cancer (1991) (24)
- Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. (2016) (24)
- Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status (2020) (24)
- Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. (2018) (24)
- NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE‐INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY: MP34‐11 (2017) (23)
- DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors (2015) (23)
- Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies (2017) (23)
- PD-L 1 expression in nonclear-cell renal cell carcinoma (2014) (23)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
- Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. (2011) (23)
- Molecular targets on the horizon for kidney and urothelial cancer (2013) (23)
- Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. (2018) (22)
- Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma (2018) (22)
- Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. (1996) (22)
- KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results. (2019) (22)
- The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. (2016) (22)
- Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. (2000) (22)
- Combination therapy in metastatic renal cell cancer. (2013) (22)
- Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents (2018) (22)
- The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. (2017) (21)
- Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. (2015) (21)
- Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. (2008) (21)
- Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities (2019) (21)
- A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. (2013) (21)
- Interferon and disseminated Langerhans cell histiocytosis. (1992) (20)
- Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. (2015) (20)
- Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. (2013) (20)
- 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy (2020) (20)
- Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. (20)
- Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database (2018) (19)
- Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer (2017) (19)
- Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy (2013) (19)
- New Treatments for Bladder Cancer: When Will We Make Progress? (2014) (19)
- Targeted therapies and the treatment of non-clear cell renal cell carcinoma. (2013) (19)
- Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. (2015) (19)
- Review: Castration-resistant prostate cancer: new science and therapeutic prospects (2010) (19)
- Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases (2018) (19)
- Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). (2018) (19)
- Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. (2021) (19)
- Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action (2012) (19)
- Overview of gemcitabine triplets in metastatic bladder cancer. (2003) (18)
- Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients (2010) (18)
- Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4 (2018) (18)
- New agents for bladder cancer. (2010) (18)
- Incidental focal uptake in colorectal location on oncologic ¹⁸FDG PET and PET/CT studies: histopathological findings and clinical significances. (2015) (18)
- Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (2017) (18)
- Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models (2019) (18)
- Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer (2013) (17)
- A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN) (2017) (17)
- Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity (1990) (17)
- Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. (2010) (17)
- A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity. (2015) (17)
- Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments (2013) (17)
- Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors (2015) (17)
- FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC). (2018) (17)
- Future developments in renal cell carcinoma. (2009) (17)
- First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. (2021) (17)
- Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. (2012) (17)
- Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (16)
- INTERMITTENT CHEMOTHERAPY IN METASTATIC ANDROGEN‐INDEPENDENT PROSTATE CANCER (2007) (16)
- Diagnosis of Bladder Carcinoma: A Clinician's Perspective. (2015) (16)
- Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. (2020) (16)
- Mitomycin-C and vinblastine in advanced breast cancer. (1989) (16)
- ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. (2017) (16)
- Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma (2016) (15)
- 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) (2020) (15)
- The clinical impact of using complex molecular profiling strategies in routine oncology practice (2018) (15)
- Phase II trial of an all‐oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer (1995) (15)
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy (2017) (15)
- Defining "cisplatin ineligible" patients with metastatic bladder cancer. (2011) (15)
- A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies (2016) (15)
- Enzalutamide in European and North American men participating in the AFFIRM trial (2014) (15)
- Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) (2015) (15)
- The Cancer Genome Atlas Project in Bladder Cancer. (2018) (15)
- Orbital metastases from transitional-cell cancer of the urinary bladder. (1991) (15)
- A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer (2013) (15)
- Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle‐invasive Urinary Bladder Cancer (2017) (15)
- Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. (2017) (15)
- KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. (2015) (14)
- Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy (2018) (14)
- Prostate cancer. Multidisciplinary approach: a key to success. (2008) (14)
- The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona (2014) (14)
- Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL (2019) (14)
- Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. (2013) (14)
- A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. (2012) (14)
- PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) (1996) (14)
- Recommendations for the optimal management of early and advanced urothelial carcinoma. (2012) (14)
- Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). (2013) (14)
- TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. (2021) (14)
- FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues (2020) (13)
- New chemotherapy combinations for advanced bladder cancer (2001) (13)
- Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. (2009) (13)
- Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? (2019) (13)
- Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. (2019) (13)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. (2014) (13)
- M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. (1996) (13)
- Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. (2019) (13)
- Statins and the effect of BCG on bladder cancer. (2007) (13)
- Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. (2016) (13)
- Experience with sorafenib and the elderly patient (2010) (13)
- The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy (2017) (13)
- Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival (2016) (12)
- Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) (2019) (12)
- Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC). (2013) (12)
- 808OINHIBITION OF PD-L1 BY MPDL3280A LEADS TO CLINICAL ACTIVITY IN PTS WITH METASTATIC UROTHELIAL BLADDER CANCER (UBC). (2014) (12)
- Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy (2011) (12)
- Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. (2015) (12)
- SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG‐rearranged prostate cancer (2019) (12)
- Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population (2018) (12)
- Pembrolizumab for Advanced Urothelial Carcinoma. (2017) (12)
- Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC (2007) (12)
- VIA.2 Prostate cancer – Multidisciplinary approach: a key to success (2007) (12)
- Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. (2015) (12)
- [Epithelioid hemangioendothelioma of the liver]. (1990) (12)
- New agents for prostate cancer. (2014) (12)
- The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine (2013) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma. (2017) (11)
- Epitheliod Hemangioendothelioma of the Liver with Mycocardial Metastases (1989) (11)
- Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer (2016) (11)
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. (2018) (11)
- Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial. (2018) (11)
- Current role of cabozantinib in metastatic castration-resistant prostate cancer (2015) (11)
- Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. (2012) (11)
- [The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival]. (1994) (11)
- Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder. (1992) (11)
- Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes (2018) (11)
- Advances in the management of high‐risk localised and metastatic prostate cancer (2012) (11)
- KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). (2016) (11)
- Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. (2014) (11)
- BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (11)
- 699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers (2020) (11)
- A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01 (2010) (10)
- KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. (2015) (10)
- Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. (2020) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis (2018) (10)
- Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. (2017) (10)
- Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. (2017) (10)
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. (2022) (10)
- Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. (2016) (10)
- Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. (2011) (10)
- Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy (2016) (10)
- Orbital metastasis, by transitional cell carcinoma of the bladder (2007) (10)
- Identification of ALK Gene Alterations in Urothelial Carcinoma (2014) (10)
- Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. (2021) (9)
- First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. (2015) (9)
- Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? (2014) (9)
- What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis (2018) (9)
- The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. (2019) (9)
- A new approach to second-line therapy for urothelial cancer? (2013) (9)
- Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer (2009) (9)
- Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. (2014) (9)
- The evolving role of enzalutamide on the treatment of prostate cancer. (2016) (9)
- Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer (2019) (9)
- Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. (1995) (8)
- Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. (2014) (8)
- PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations. (2020) (8)
- Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study (2011) (8)
- A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). (2021) (8)
- Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib (2020) (8)
- Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). (2014) (8)
- First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. (2010) (8)
- PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma. (2014) (8)
- IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC) (2016) (8)
- Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity. (1991) (8)
- Precision and predictive medicine in urothelial cancer: are we making progress? (2015) (8)
- FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (8)
- The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma (2008) (8)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. (2017) (7)
- Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer. (2014) (7)
- Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. (2017) (7)
- An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC) (2005) (7)
- Practical aspects of metastatic castration‐resistant prostate cancer management: patient case studies (2012) (7)
- Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials. (2016) (7)
- Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer (2017) (7)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy (2017) (7)
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. (2022) (7)
- Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303. (2018) (7)
- KEYNOTE-361: Phase 3 trial of pembrolizumab ± chemotherapy versus chemotherapy alone in advanced urothelial cancer (2018) (7)
- Epithelioid hemangioendothelioma of the liver with myocardial metastases. (1989) (6)
- Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. (2018) (6)
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. (2017) (6)
- 7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib (2011) (6)
- Predictive modelling in hormone-refractory prostate cancer (HRPC) (2009) (6)
- Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma (2020) (6)
- Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)—Interim analysis on safety. (2014) (6)
- Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. (2008) (6)
- Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI) (1996) (6)
- Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis (1997) (6)
- Maximizing outcomes in genitourinary cancers across the treatment continuum (2011) (6)
- LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy (2020) (6)
- LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial (2017) (6)
- Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? (2009) (6)
- Bladder cancer. (2015) (6)
- Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). (2016) (6)
- Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)—SOGUG 2011-02. (2015) (5)
- Pembrolizumab in the treatment of advanced urothelial cancer. (2017) (5)
- Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. (2018) (5)
- Targeting DNA Damage Repair Mechanisms in Pancreas Cancer (2021) (5)
- Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT). (2014) (5)
- Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
- Avelumab for the treatment of urothelial cancer (2018) (5)
- New advances in genitourinary cancer: evidence gathered in 2014 (2015) (5)
- 812PDMATURE SURVIVAL (OS) DATA OF A RANDOMISED INTERNATIONAL PHASE II TRIAL (JASINT1): VINFLUNINE (VFL)-GEMCITABINE (GEM) VS. VFL-CBDCA IN CDDP-UNFIT PATIENTS (PTS) WITH ADVANCED UROTHELIAL CARCINOMA (UC). (2014) (5)
- Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). (2014) (5)
- Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma (2010) (5)
- RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. (2021) (5)
- Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen (2014) (5)
- Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy. (2018) (5)
- Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. (2014) (5)
- False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. (2013) (5)
- MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER (2015) (5)
- [Spinal cord compression as a primary manifestation of occult thyroid carcinoma]. (1992) (5)
- Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. (2015) (5)
- 13 UPDATED SURVIVAL RESULTS OF THE PHASE III TRIAL COMPARING VINFLUNINE (V) TO BEST SUPPORTIVE CARE (BSC) IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM (TCCU) AFTER FAILURE OF A PRIOR PLATINUM-CONTAINING REGIMEN (2010) (5)
- Perioperative therapy for muscle invasive bladder cancer. (2015) (5)
- Colangiocarcinoma periférico: resultados del tratamiento quirúrgico (2006) (5)
- Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. (2016) (5)
- 857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status (2017) (5)
- Reply to G. Sonpavde et al (2010) (5)
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. (2021) (5)
- Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. (2019) (5)
- Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. (2017) (5)
- A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. (2013) (4)
- Sunitinib in renal-cell carcinoma: expanded indications. (2009) (4)
- 851PDSubgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) (2017) (4)
- Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome (2019) (4)
- Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management. (2022) (4)
- Sunitinib malate in the treatment of urothelial cancer (2014) (4)
- PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. (2020) (4)
- Sorafenib TARGET Trial results in Spanish patients (2007) (4)
- Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain (2013) (4)
- Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence (2008) (4)
- Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors (2017) (4)
- Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. (2014) (4)
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. (2010) (4)
- Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. (2013) (4)
- Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis (2022) (4)
- 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052 (2020) (4)
- Cancer immunotherapy: new applications in urologic oncology (2016) (4)
- Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (4)
- Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. (2002) (4)
- Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. (2012) (4)
- Immunotherapy in non-metastatic urothelial cancer: back to the ‘future’ (2019) (4)
- 7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN (2009) (4)
- 919TiPPembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial (2017) (4)
- Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. (2011) (4)
- Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era. (2021) (4)
- Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). (2019) (4)
- A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes. (2015) (4)
- Metastatic urothelial carcinoma. (2021) (4)
- MP61-09 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN AND ROBOT-ASSISTED RADICAL CYSTECTOMIES: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES (2014) (4)
- Antiangiogenesis to curb urothelial cancer (2017) (4)
- Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis (2016) (4)
- Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? (2015) (4)
- First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment (2007) (4)
- Erratum: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma [Journal for Immunotherapy of Cancer., 5 (2017)(68)] DOI: 10.1186/s40425-017-0271-0 (2017) (4)
- [Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]. (1992) (4)
- Fatal septic thrombophlebitis due toSalmonella enteritidis (2005) (4)
- Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. (2010) (4)
- Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma (2015) (4)
- FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. (2020) (4)
- Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. (2020) (4)
- [Peripheral cholangiocarcinoma: results of surgical treatment]. (2006) (3)
- Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (2011) (3)
- Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first‐line metastatic renal carcinoma (SUNRISES study) (2020) (3)
- 7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival (2009) (3)
- Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease. (2021) (3)
- Treatment of Metastatic Urothelial Cancer in 2018. (2019) (3)
- Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. (2015) (3)
- Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (2015) (3)
- Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer? (2015) (3)
- Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder (2021) (3)
- 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) (2016) (3)
- Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02 (2016) (3)
- Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2015) (3)
- Enhanced Bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy (2021) (3)
- Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. (2019) (3)
- 789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING. (2014) (3)
- Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6. (2014) (3)
- Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. (2015) (3)
- Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder (2022) (3)
- 856 SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) AND PRIOR CYTOKINE THERAPY: SUBGROUP ANALYSIS OF TARGETS (2007) (3)
- First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts). (2018) (3)
- Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. (2009) (3)
- Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)--SOGUG 2011-02. (2016) (3)
- Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma (2018) (3)
- Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 (2017) (3)
- Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database (2016) (3)
- Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival. (2017) (3)
- Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. (2022) (3)
- Genitourinary tumors, prostate (2012) (3)
- 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting (2015) (3)
- An exploratory study of radium-223 and vascular endothelial growth factor targeted therapy (VEGF TT) in patients (pts) with metastatic renal cell carcinoma (mRCC) and bone metastases (BM). (2017) (3)
- Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis (2017) (3)
- 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy (2021) (3)
- Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100. (2021) (3)
- 718 SORAFENIB (SOR) DOSAGE PATTERNS IN OLDER PATIENTS (PTS) WITH ADVANCED RENAL CELL CARCINOMA (RCC): A SUBANALYSIS BY AGE OF AN INTEGRATED DATABASE OF 8 COMPANY-SPONSORED CLINICAL TRIALS (2011) (3)
- ALK chromosomal alterations in colon cancer patients. (2010) (3)
- Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study. (2009) (3)
- Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer. (2020) (3)
- Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer (2020) (3)
- Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations (2010) (3)
- Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma (1998) (3)
- Systematic review of quality of life outcomes after primary treatment for clinically localised prostate cancer (2018) (3)
- Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. (2019) (2)
- [Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult]. (1990) (2)
- Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. (2018) (2)
- The optimize project: beyond first-line therapy in metastatic renal cell carcinoma (2012) (2)
- Faculty List (2018) (2)
- Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer (2009) (2)
- Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial. (2013) (2)
- [Current strategies in the treatment of renal-cell cancer: targeted therapies]. (2008) (2)
- Cell-free tumor DNA and TERT promoter mutations in bladder cancer. (2017) (2)
- Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). (2013) (2)
- Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) (2020) (2)
- An international collaborative study from the EAU and ESMO to develop consensus statements for muscle invasive bladder cancer (2019) (2)
- Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors. (2014) (2)
- Chemotherapy in Metastatic Urothelial Cancer (2002) (2)
- Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma. (2018) (2)
- Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy. (2022) (2)
- Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) versus single agent and doublet chemotherapy (CT). (2017) (2)
- ALK chromosomal alterations in neuroendocrine tumors. (2011) (2)
- 7121 Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC) (2009) (2)
- Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (2)
- Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. (2020) (2)
- External Validation of the Association of Progression-Free Survival at 6 Months (PFS6) with Overall Survival at 12 Months (OS12) in Second-Line Therapy for Advanced Urothelial Carcinoma (UC) (2012) (2)
- A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma (2017) (2)
- Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway and prognostic significance for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial cancer (UC). (2014) (2)
- TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy. (2022) (2)
- Prognostics factors in previously untreated urothelial cancer patients ineligible for cisplatin-based chemotherapy: An external validation of the Bajorin risk groups. (2013) (2)
- Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel. (2012) (2)
- Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). (2015) (2)
- Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. (1997) (2)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy. (2016) (2)
- The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer. (2015) (2)
- 854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm) (2017) (2)
- Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis. (2004) (2)
- Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. (2015) (2)
- Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II. (2013) (2)
- Long-term survival results of a randomized phase III trial of vin fl unine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy † (2013) (2)
- Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. (2022) (2)
- Exploring Patterns of Mitomycin C Use in Community Practice Urology (2018) (2)
- SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence (2021) (2)
- Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma (2021) (2)
- Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU). (2011) (2)
- Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study (2017) (2)
- From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta‐analysis (2017) (1)
- Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial. (2022) (1)
- miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel. (2015) (1)
- 656 RANDOMIZED PHASE III TRIAL COMPARING ADJUVANT PACLITAXEL/GEMCITABINE/CISPLATIN (PGC) TO OBSERVATION IN PATIENTS WITH RESECTED INVASIVE BLADDER CANCER: RESULTS OF THE SOGUG-GUO-AEU 99/01 TRIAL (2011) (1)
- Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). (2016) (1)
- 861 Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 (2014) (1)
- MP65-12 AN OPTIMIZED TREATMENT STRATEGY FOR HGT1 BLADDER CANCER BASED ON MICROSTAGING: RESULTS AT 5YEARS FOLLOW-UP IN 200 PATIENTS (2014) (1)
- Current Therapy for Metastatic Urothelial Carcinoma. (2021) (1)
- Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC). (2019) (1)
- Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors. (2016) (1)
- Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients (2005) (1)
- A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. (2015) (1)
- Adjuvant chemotherapy for invasive bladder cancer (2015) (1)
- Vinflunine maintenance therapy versus best supportive care (BSC) after platinum combination in advanced bladder cancer: A phase II, randomized, open-label study (MAJA study)—SOGUG 2011-02. (2012) (1)
- Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (2011) (1)
- Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy. (2015) (1)
- Genomic predictors of recurrence (R) or progression (P) in high grade T1 (HGT1) non-muscle invasive (NMI) bladder cancer. (2016) (1)
- Cytotoxic Chemotherapy for Advanced Bladder and Upper Tract Cancer (2021) (1)
- [Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure]. (1997) (1)
- Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study (2012) (1)
- Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. (2016) (1)
- Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials. (2015) (1)
- An investigator-initiated phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before or after progression on docetaxel. (2016) (1)
- 799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations (2020) (1)
- Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA (2013) (1)
- Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. (2020) (1)
- Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? (2022) (1)
- Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor (2012) (1)
- PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL (2022) (1)
- Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (mRCC): A phase II study of sorafenib, gemcitabine (Gem), and metronomic capecitabine (Cap) in patients with advanced mRCC (SOGUG-02-06). (2009) (1)
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. (2018) (1)
- Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder (2017) (1)
- Phase Ib study of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer progressing after one line of chemotherapy and one novel androgen receptor axis inhibitor. (2018) (1)
- MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES (2014) (1)
- Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2016) (1)
- Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications. (2016) (1)
- Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (1)
- Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy. (2016) (1)
- Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052 (2018) (1)
- 11C‐METHIONINE POSITRON‐EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET‐CT) IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY (2010) (1)
- Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets. (2019) (1)
- Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). (2019) (1)
- [Advanced bladder cancer: new therapeutic strategies]. (2003) (1)
- Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC) (2016) (1)
- Genomic characterization of metastatic urothelial carcinoma. (2013) (1)
- Use of Bone Health Agents (BHAs) in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Radium-223 after Abiraterone: An Interim Review of Reassure (2019) (1)
- External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer (2022) (1)
- IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC) (2017) (1)
- Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer. (2017) (1)
- Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. (2022) (1)
- Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC). (2016) (1)
- Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis. (2017) (1)
- Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry. (2020) (1)
- [Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer]. (1998) (1)
- Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
- Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). (2015) (1)
- FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians. (2018) (1)
- Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer (2014) (1)
- Neo-adjUvant veRsus AdjuvaNt chemotherapy in upper tract Urothelial carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”) (2019) (1)
- Advances in the management of urothelial carcinoma: is immunotherapy the answer? (2021) (1)
- Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. (2023) (1)
- Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. (2016) (1)
- Latest progress in molecular biology and treatment in genitourinary tumours (2020) (1)
- 7114 POSTER DISCUSSION Appropriateness of Treatment Options for the Management of Patients With Advanced Renal Cell Carcinoma (RCC) Using the Validated Semi Quantitative RAND Corporation/University of California, Los Angeles (RAND/UCLA) Methodology (2011) (1)
- Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience. (2014) (1)
- 708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC) (2021) (1)
- Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." (2018) (1)
- Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. (2022) (1)
- Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial (2017) (1)
- Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply. (2021) (1)
- 進行性尿路上皮癌(UC)患者(pts)におけるゲムシタビン/カルボプラチン(GC)とメトトレキサート/カルボプラチン/ビンブラスチン(M-CAVI)を比較する無作為化第2/3相試験は,シスプラチンに基づいた化学療法(CHT)に適さない:EORTC30986第3相試験の結果 (2010) (1)
- Does it matter whether a T1 high-grade tumor is molecularly classified? (2019) (1)
- Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel. (2012) (1)
- Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). (2013) (1)
- 875POutcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population (2017) (1)
- Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy. (2013) (1)
- MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302 (2014) (1)
- Intravenous vinorelbine (i.v.VRL) and estramustine (EMP) in patients (pts) with androgen-independent prostate cancer (AIPC): final results (2001) (1)
- Nailfold capillary microscopy and bleomycin-induced vascular toxicity. (1990) (1)
- Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) with metastatic urothelial cancer (mUC). (2019) (1)
- 866PImpact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) (2017) (1)
- C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab (2022) (1)
- COMPARATIVE EFFECTIVENESS OF SELECTIVE ADJUVANT VERSUS SYSTEMATIC NEOADJUVANT CHEMOTHERAPY‐BASED STRATEGY FOR MUSCLE‐ INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER: PD62‐01 (2017) (1)
- Adjuvant chemotherapy improves survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for bladder cancer: Results of a multi-institutional collaboration (2019) (0)
- hemotherapy for Bladder Cancer : reatment Guidelines for Neoadjuvant hemotherapy , Bladder Preservation , djuvant Chemotherapy , and Metastatic ancer (2007) (0)
- Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma (2018) (0)
- MP13-14 THE IMPACT OF SURGEON VOLUME ON THE MORBIDITY AND COSTS OF NEPHROURETERECTOMY IN THE UNITED STATES: A CONTEMPORARY POPULATION-BASED ANALYSIS (2014) (0)
- The treating scenario in genitourinary oncology: what is new? Part 1. (2013) (0)
- Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles. (2016) (0)
- Immunosuppression with cyclosporin A and pregnancy (1990) (0)
- Abstract 2918: Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature (2017) (0)
- Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI). (2016) (0)
- Adjuvant chemotherapy plus radiotherapy versus chemotherapy alone for locally advanced bladder cancer after radical cystectomy (2022) (0)
- LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC) (2022) (0)
- Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). (2023) (0)
- F24 Metastatic renal cell cancer: SIOG position paper (2009) (0)
- 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) (2020) (0)
- Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology (2019) (0)
- PD26-06 ADJUVANT CHEMOTHERAPY PLUS RADIOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR LOCALLY ADVANCED BLADDER CANCER AFTER RADICAL CYSTECTOMY (2022) (0)
- In reply. (2014) (0)
- MP60-14 TRENDS IN URINARY DIVERSION AMONG PATIENTS UNDERGOING RADICAL CYSTECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS (2014) (0)
- PD22-04 IMMEDIATE RADIOTHERAPY VERSUS OBSERVATION IN PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY (2022) (0)
- Morphological differences in the vascularization of tuberculoma and tuberculous brain abscess (1990) (0)
- Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival (2017) (0)
- Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial. (2017) (0)
- [New cell target treatments: indications, results and tolerance]. (2009) (0)
- [Antineoplastic chemotherapy in digestive tumors]. (1991) (0)
- MP59-08 DISPARITIES IN THE PREVALENCE AND MANAGEMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (2022) (0)
- PD11-09 RACIAL DISPARITIES IN QUALITY OF CARE AND OVERALL SURVIVAL AMONG MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: A NATIONAL CANCER DATABASE ANALYSIS (2018) (0)
- Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361. (2022) (0)
- 7162 POSTER A Pan-European Study of Treatment (trx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) (2011) (0)
- Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study. (2012) (0)
- Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). (2018) (0)
- Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. (2011) (0)
- MP65-14 PROPOSAL FOR INCLUDING SUBSTAGING OF HGT1 BLADDER CANCER IN THE TNM CLASSIFICATION: A SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON 2678 PATIENTS (2014) (0)
- Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.08.033. (2020) (0)
- Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens. (2021) (0)
- PCN13 A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (2009) (0)
- Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC). (2016) (0)
- 1004 Impact of BCG therapy in high-grade T1 bladder cancer: A meta-analysis based on 2,687 patients (2014) (0)
- [Gene therapy: new prospects in the treatment of cancer]. (1994) (0)
- Mitogen-activated protein kinase phosphatase-1 (MKP-1) as a biomarker of resistance to cetuximab in colorectal cancer patients. (2010) (0)
- MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100 (2021) (0)
- Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC). (2016) (0)
- Genomic landscape of micropapillary nonmuscle-invasive bladder cancer. (2016) (0)
- Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. (2015) (0)
- Metastatic prostate cancer. Summary of Science for Practice (2016) (0)
- MP32-12 ROBOTIC VERSUS OPEN RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER (2023) (0)
- Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC. (2018) (0)
- Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (0)
- 631P Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study (2021) (0)
- 932 High dose continuous infusion (CI) ifosfamide without hematopoietic support in heavily pretreated breast cancer (BC) and sarcoma (S) patients (1995) (0)
- Differential expression of SRSF2 contribute to the splicing changes related to micropapillary variant histology in nonmuscle-invasive bladder cancer (NMIBC). (2018) (0)
- [Acromegaly and lung cancer]. (1989) (0)
- IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab (2022) (0)
- Comprehensive genomic characterization of urothelial carcinomas. (2018) (0)
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. (2023) (0)
- 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC) (2020) (0)
- New advances in genitourinary cancer: evidence gathered in 2014 (2015) (0)
- Molecular answers and targets on the horizon for the treatment of genitourinary malignancies (2012) (0)
- Immunosuppressed Microenvironment – An Emerging Target in Prostate Cancer Management (2014) (0)
- Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials. (2022) (0)
- 2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT) (2015) (0)
- The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT). (2016) (0)
- 253 A PATIENT-FOCUSED APPROACH: OPTIMIZING SORAFENIB TREATMENT OUTCOMES IN RENAL CELL CARCINOMA (RCC) (2009) (0)
- [Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma]. (1994) (0)
- Title : The Prognostic Role of Epigenetic dysregulation in Bladder Cancer : A Systematic Review (2017) (0)
- Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. (2018) (0)
- Editorial Comment. (2020) (0)
- RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987 (2012) (0)
- 642 A CONSENSUS DEFINITION FOR CASTRATION-RESISTANT PROSTATE CANCER. “DELPHI STUDY” (2011) (0)
- Hormone-refractory Prostate Cancer (2004) (0)
- Reply to K. Lu. (2015) (0)
- Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis. (2015) (0)
- Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design. (2013) (0)
- Randomized phase II study of maintenance vinflunine versus best supportive care after first line chemotherapy in patients with advanced urothelial carcinoma : The MAJA study ( SOGUG 2011 / 02 ) (2017) (0)
- Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02). (2018) (0)
- The treating scenario in genitourinary oncology: what is new? Part 2. (2013) (0)
- Predictors for survival with cabazitaxel (CBZ) in metastatic, castration-resistant prostate cancer (mCRPC): Long term follow-up of the Spanish registry. (2017) (0)
- COMPARATIVE EFFECTIVNESS OF ROBOT‐ASSISTED VS. OPEN RADICAL CYSTECTOMY: PD67‐09 (2017) (0)
- 1101 Prognostic factors for high-grade T1 bladder cancer: A meta-analysis based on 7,486 patients (2014) (0)
- Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies. (2014) (0)
- What are the expected developments in the medical treatment of bladder cancer. (2011) (0)
- [Primary non-Hodgkin's lymphoma of the breast]. (1993) (0)
- Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials. (2017) (0)
- Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. (1997) (0)
- Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). (2013) (0)
- PD09-05 STANDARD VERSUS EXTENDED LYMPH NODE DISSECTION AT THE TIME OF RADICAL CYSTECTOMY FOR BLADDER CANCER (2023) (0)
- Prognostic impact of primary tumor location in advanced urothelial tract cancer (UCC); a pooled analysis of EORTC 30924, 30986, and 30987 trials (2017) (0)
- Identification of ALK gene alterations in urothelial carcinoma (UC). (2011) (0)
- Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. (2022) (0)
- Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results. (2014) (0)
- MP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA (2017) (0)
- Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? (2016) (0)
- Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
- Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052. (2022) (0)
- Secular trends in survival in prostate cancer (PC) (1992-2005) in a public hospital in Barcelona: Impact of PSA implementation and hormone-radiotherapy (HT+RT) treatment introduction--An observational study (2007) (0)
- [Solitary cerebellar metastases: a clinical neuro-radiological study]. (1988) (0)
- PD09-10 AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY (2023) (0)
- Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC). (2015) (0)
- Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (2015) (0)
- [Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus]. (1990) (0)
- MP22-12 THE ASSOCIATION OF BASELINE FRAILTY WITH SURVIVAL AMONG OLDER ADULTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2023) (0)
- COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE‐INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER: PD62‐12 (2017) (0)
- IIIA.3 The medical treatment of metastatic renal cell in the elderly: position paper of a SIOG Taskforce (2007) (0)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. (2014) (0)
- Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens. (2020) (0)
- 'Working toward understanding oligo and polymetastatic prostate cancer'. (2017) (0)
- ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis. (2015) (0)
- PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA (2016) (0)
- Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer (2017) (0)
- Chemotherapy treatment patterns and survival outcomes in patients with visceral metastatic upper tract urothelial cell carcinoma. (2016) (0)
- Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. (2016) (0)
- Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study. (2011) (0)
- Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine. (2012) (0)
- Assessing the value of routine perioperative creatinine monitoring in clinical decision-making for patients undergoing radical nephrectomy (2022) (0)
- 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) (2015) (0)
- Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. (2023) (0)
- Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials. (2014) (0)
- IL-5 (S) Molecular Targeting Therapy to RCC : Current Status and Future Perspectives (2007) (0)
- Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder (2017) (0)
- Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.020. (2021) (0)
- Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series. (2017) (0)
- Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer (2022) (0)
- External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC). (2014) (0)
- EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA: MP71‐09 (2017) (0)
- 1165 Multidrug resistance in bladder cancer: Role of P-glycoprotein in the response to chemotherapy (1995) (0)
- The optimize project: beyond first-line therapy in metastatic renal cell carcinoma (2012) (0)
- Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis. (2017) (0)
- Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. (2012) (0)
- 1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100 (2022) (0)
- [The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications]. (1996) (0)
- 899 Microstaging HGT1 bladder cancer allows for a more tailored treatment: Results of an optimized strategy at 5y follow-up in 200 patients (2014) (0)
- Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302). (2022) (0)
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) (2018) (0)
- Abstract 1168: Urothelial cell carcinomas harbor very frequent mutations in FGFR3-PI3K-AKT pathway and highest prevalence of mutations is related to low-grade tumors (2010) (0)
- Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC). (2015) (0)
- Phase 2 study of pembrolizumab in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer: KEYNOTE-057 (2018) (0)
- Unfavourable cancer specific survival after neoadjuvant chemotherapy and radical cystectomy in bladder cancer patients with squamous-cell variant: A multi-institutional study (2021) (0)
- Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer (2015) (0)
- Targeting the PI3K/AKT/mTOR pathway with a dual mTORC1/2 inhibitor in bladder cancer. Rationale for its testing in clinical trials (2016) (0)
- Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib. (2014) (0)
- Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study (2016) (0)
- 7133 POSTER Treatment (tx) Patterns and Toxicity of Angiogenesis Inhibitors in Patients (pts) With Advanced Renal Cell Carcinoma (RCC) in Spain (2011) (0)
- Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action (2012) (0)
- MP42-15 UROTHELIAL CARCINOMA OF THE BLADDER WITH ISOLATED LYMPH NODE METASTASIS: NATURAL HISTORY AND OUTCOMES FOLLOWING SURGICAL RESECTION (2022) (0)
- Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report. (2016) (0)
- MP41-13 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL (2021) (0)
- Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. (2023) (0)
- 41 Localized invasive bladder cancer: neo-adjuvant chemotherapy? (2011) (0)
- Malignant lymphoproliferative diseases (MLD) in patients seropositive for the HIV (1993) (0)
- Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design. (2018) (0)
- Abstract 4066: Loss of Sh3gl2/endophilin A1 is an early event in urothelial carcinoma that regulates malignant behavior. (2013) (0)
- Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). (2013) (0)
- [Glycoprotein P and resistance to antitumor chemotherapy]. (1993) (0)
- Phase II Clinical and Pharmacokinetic (PK) Trial of Zalypsis (Z) in Patients with Urothelial Carcinoma (UC) Progressing after a First-Line Platinum-Based Regimen (2012) (0)
- Bladder Cancer: Upper Tract Transitional Cell Carcinoma IMP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA (2017) (0)
- A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. (2022) (0)
- Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study. (2017) (0)
- MP63-06 RACIAL DISPARITIES IN QUALITY METRICS OF MUSCLE INVASIVE BLADDER CANCER (2016) (0)
- Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study. (2011) (0)
- Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2017) (0)
- Correction: Corrigendum: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer (2012) (0)
- 1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study (2022) (0)
- [Corticoid treatment in Castleman's disease]. (1995) (0)
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma (2018) (0)
- 1277 Transduction and selection of murine tumor cells engineered to express the interleukin 2 (IL-2) and herpes simplex virus thymidine kinase (HSVTK) genes (1995) (0)
- Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. (2014) (0)
- Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT) (2017) (0)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (0)
- A FISH study reveals ALK gains in colon cancer patients (2010) (0)
- 888PChange in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC) (2017) (0)
- Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy (2017) (0)
- The Khorana score in predicting venous thromboembolism for metastatic urothelial carcinoma and variant histology patients treated with chemotherapy (2017) (0)
- [Symptomatic hypomagnesemia in a patient treated with cisplatin]. (1990) (0)
- [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung]. (1991) (0)
- Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multi-country retrospective medical chart review (2023) (0)
- [Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases]. (1994) (0)
- Genomic landscape of high-grade T1 micropapillary bladder tumors. (2015) (0)
- 94 A REAL-LIFE COMPARATIVE EFFECTIVENESS SIMULATION OF PROGRESSION FREE SURVIVAL COMPARING FIRST-LINE SUNITINIB VS. BEVACIZUMAB + INTERFERON-ALPHA 2A IN METASTATIC RENAL CELL CARCINOMA-CONSIDERING THE EFFECTS OF DOWN-DOSING AND PATIENT COMPLIANCE (2010) (0)
- DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors (2015) (0)
- Gemcitabine/cisplatin in patients with advanced bladder and impaired renal function: A retrospective analysis. (2010) (0)
- Phase I study of bi-weekly pemetrexed (P) plus cisplatin (C) in patients with advanced cancer (2007) (0)
- 865PTHE SIGNIFICANCE OF COMPLETE RESPONSE (CR) IN PATIENTS RECEIVING SALVAGE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC). (2014) (0)
- Advances in the Management of Metastatic Renal Cell Cancer (2009) (0)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (0)
- Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States (2017) (0)
- 867POUTCOMES WITH CISPLATIN-BASED FIRST-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC) FOLLOWING PREVIOUS PERIOPERATIVE CISPLATIN-BASED THERAPY. (2014) (0)
- Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. (2009) (0)
- ADJUVANT CHEMOTHERAPY VS. OBSERVATION FOLLOWING RADICAL CYSTECTOMY FOR PT3‐4 AND/OR PN+ UROTHELIAL CARCINOMA OF THE BLADDER PREVIOUSLY TREATED WITH NEOADJUVANT CHEMOTHERAPY: PD62‐02 (2017) (0)
- Editorial introductions. (2017) (0)
- Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. (2012) (0)
- Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study (2022) (0)
- A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). (2017) (0)
- P57 Elderly patients with advanced renal cell carcinoma (RCC): combined experience with sorafenib from the randomized phase III TARGET and the European (EU) and North American (NA) Open-Access (ARCCS) trials (2009) (0)
- Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder (2022) (0)
- Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drugs Advisory Committee Reviews Reply (2014) (0)
- Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) (2016) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2018) (0)
- Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma (2019) (0)
- 26 Chemotherapy options in cisplatin-unfit patients with advanced urothelial cell cancer (2009) (0)
- Abstract 3662: FiTAc-seq: Fixed-Tissue ChIP-seq for H3K27Ac profiling and super-enhancer analysis on FFPE tissues (2020) (0)
- Clinical utility of complex multi-platform profiling in metastatic cancer patients. (2018) (0)
- 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel (2015) (0)
- MP42-17 CONDITIONAL SURVIVAL FOLLOWING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER (2022) (0)
- Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC). (2020) (0)
- EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON‐METASTATIC MUSCLE‐INVASIVE URINARY BLADDER CANCER: MP34‐19 (2017) (0)
- Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients. (2016) (0)
- 2255 : Consolidative Chemo-Radiotherapy Improves Locoregional Control in Pelvic Relapse or Incompletely Resected Transitional Bladder Cancer After Maximum Response to Chemotherapy (2006) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joaquim Bellmunt?
Joaquim Bellmunt is affiliated with the following schools:
